References
- Kosmas I, Kitsou C, Lazaros L, et al. Everolimus, an mTOR pathway inhibitor, is highly successful on ovarian hyperstimulation syndrome by reducing ovarian weight and progesterone levels: a preclinical experimental randomized controlled study. Gynecol Endocrinol 2015;31:702–7
- Kitsou C, Kosmas I, Lazaros L, et al. Ovarian hyperstimulation syndrome inhibition by targeting VEGF, COX-2 and Calcium pathways: a preclinical randomized study. Gynecol Endocrinol 2014;30:587–92
- Kovarik JM, Beyer D, Bizot MN, et al. Pharmacokinetic interaction between verapamil and everolimus in healthy subjects. Br J Clin Pharmacol 2005;60:434–7
- Garrison RN, Galloway RH, Heuser LS. Mechanisms of malignant ascites production. J Surg Res 1987;42:126–32
- Gomez R, Simon C, Remohi J, Pellicer A. Vascular endothelial growth factor receptor-2 activation induces vascular permeability in hyperstimulated rats, and this effect is prevented by receptor blockade. Endocrinology 2002;143:4339–48
- Zhang Z, Yu D, Yin D, Wang Z. Activation of PI3K/mTOR signaling pathway contributes to induction of vascular endothelial growth factor by hCG in bovine developing luteal cells. Anim Reprod Sci 2011;125:42–8
- Yoshimura Y, Nakamura Y, Ichikawa F, et al. Possible involvement of leukotrienes in human luteal function. Acta Endocrinol (Copenh) 1992;127:246–51
- Guardia O, Rial MC, Casadei D. Pregnancy under sirolimus-based immunosuppression. Transplantation 2006;81:636
- Sifontis NM, Coscia LA, Constantinescu S, et al. Pregnancy outcomes in solid organ transplant recipients with exposure to mycophenolate mofetil or sirolimus. Transplantation 2006;82:1698–702
- Framarino-dei-Malatesta M, Derme M, Manzia TM, et al. Impact of mTOR-I on fertility and pregnancy: state of the art and review of the literature. Expert Rev Clin Immunol 2013;9:781–9
- Jurgens TP, Schaefer C, May A. Treatment of cluster headache in pregnancy and lactation. Cephalalgia 2009;29:391–400
- Kovarik JM, Beyer D, Schmouder RL. Everolimus drug interactions: application of a classification system for clinical decision making. Biopharm Drug Dispos 2006;27:421–6
- Matousek M, Mitsube K, Mikuni M, Brannstrom M. Inhibition of ovulation in the rat by a leukotriene B(4) receptor antagonist. Mol Hum Reprod 2001;7:35–42
- Bonnefoi MS, Kelley MF, Wells RE, et al. Subchronic toxicity studies with the leukotriene D4 antagonist RG 12525. Fundam Appl Toxicol 1995;28:129–38
- Sakai M, Martinez-Arguelles DB, Patterson NH, et al. In search of the molecular mechanisms mediating the inhibitory effect of the GnRH antagonist degarelix on human prostate cell growth. PLoS One 2015;10:e0120670
- Wu HM, Wang HS, Soong YK, et al. Gonadotrophin-releasing hormone antagonist induces apoptosis in human decidual stromal cells: effect on GADD45α and MAPK signaling. Hum Reprod 2012;27:795–804
- Garrel G, Simon V, Thieulant ML, et al. Sustained gonadotropin-releasing hormone stimulation mobilizes the cAMP/PKA pathway to induce nitric oxide synthase type 1 expression in rat pituitary cells in vitro and in vivo at proestrus. Biol Reprod 2010;82:1170–9
- Nelson SM, Greer IA. The potential role of heparin in assisted conception. Hum Reprod Update 2008;14:623–45
- Genazzani AR, Monteleone P, Papini F, Artini PG. Pharmacotherapy of ovarian hyperstimulation syndrome. Expert Opin Pharmacother 2010;11:2527–34
- Pietrowski D, Szabo L, Sator M, et al. Ovarian hyperstimulation syndrome is correlated with a reduction of soluble VEGF receptor protein level and a higher amount of VEGF-A. Hum Reprod 2012;27:196–9